Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Graeme Bell, age 58, is an Independent Director and Audit Committee Chair of Averin Capital Acquisition Corp. (NASDAQ: ACAAU), a Cayman Islands blank-check company that raised $250 million in its February 2026 IPO to pursue a business combination at the intersection of technology and health. He was appointed to the board effective February 19, 2026, and also serves on the Compensation Committee. In his current executive role, Mr. Bell has served as Group Chief Financial Officer of Owkin, Inc. since May 2025, an AI and computational biology company with offices in London, Paris, New York, and Boston. He is the Founder and Principal of ValueCycle LLC and holds several additional board and advisory positions: Director at Cytoimmune Therapeutics, Inc. (since 2023), board member of Mindstate Design Labs Inc. (since December 2025), Board Advisor to Symbiotix Health Ltd. (since March 2025), and University-Appointed Mentor at Loughborough University Science and Enterprise Park (since September 2024).
Mr. Bell's career spans over three decades in biotechnology finance and operations. From 2020 to 2024, he held senior executive roles at Valo Health Inc., including Interim President and CEO in 2024 and EVP positions spanning COO, CFO, CHRO, and broader corporate functions. Prior to Valo, he served as EVP and CFO of Tmunity Therapeutics Inc., Intellia Therapeutics Inc. (NASDAQ: NTLA), and Anacor Pharmaceuticals Inc. (which was acquired by Pfizer in 2016 for approximately $5.2 billion). Earlier in his career, he spent over 20 years at Merck & Co., Inc. in finance and investor relations leadership roles. His insider trading activity reflects his deep involvement in the sector: 2015 was his most active year for acquiring shares with four transactions, and in 2016 he disposed of 82,343 shares for a total of approximately $1.12 million. His estimated net worth is reported at $1.05 million based on reported shares across Anacor Pharmaceuticals, Intellia Therapeutics, and Averin Capital Acquisition Corp. Mr. Bell holds an M.B.A. in Finance and Marketing from Durham University Business School and is a Fellow of the Chartered Institute of Management Accountants (FCMA).
This record is keyed to SEC CIK 0001643757 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 4 institutional-holder rows on these vehicles, under 3 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.